Corporate Video +/- 20 minutes Job # 2182

Job Posting Details

Job # 2182 Corporate Video +/- 20 minutes

Posted Date
Sep 30, 2006 @ 00:40
Respond By
Oct 2, 2006
Word Count
Age Range

Job Description

We are interested in American accented speakers. The script is a pharmaceutical product presentation. Since this is a technical read, we would appreciate a custom demo. The full script is provide for quoting purposes, but only a small sample needs to be read. Please include your cost estimate and your contact info with your submission. (Important: MSN or Skype).

FULL Script


Bovine respiratory illnesses represent significant losses for the worldwide cattle industry.

These losses reach billions of dollars as a result of excessive morbidity and mortality and consequent reduction in weight gain.

In addition to cattle that are clinically sick, many cattle have sub-clinical infections.

These illnesses also strongly affect new cattle that are less than one-year of age. For example, year-old calves with clinical signals of respiratory illness gain an average of 0.04kg per day less than a healthy peer in the same herd.

Dairy cattle can be affected as much as the beef cattle. The illness may also spread quickly among the animals.
Many risk factors contribute to the development of BRD. But the determining cause is a combination of environmental stress combined with viral and bacterial infection.

Short term or acute disease in cattle plays a fundamental role in the BRD Management complex. However, long term damage can also occur with these animals, leading to slower growth and performance.

Schering-Plough is in the vanguard of research on respiratory treatments for human beings and animals, as well as on pharmaceutical research that can help in the control and management of the respiratory complex. The interchange of knowledge between Schering-Plough and opinion leaders at major Universities and Institutions of Research around of the world, allows our scientists to use the concepts, techniques and tools that are most up-to-date.

Resflor is the newest product of Schering-Plough Animal Health.

It is the result of a multidisciplinary effort of scientists and practicing field veterinarians.

The new product from Schering–Plough


Fast and Visible Recovery
Resflor is a new class of solution within the category of Lung Protection Therapy.
Resflor provides incomparable levels of clinical recovery.
Resflor is effectively the new standard for BRD management.

1. Anatomy and Physiology of the Respiratory Tract

A healthy Respiratory System ensures an adequate gas exchange so that oxygen is efficiently absorbed and carbon dioxide is eliminated.

When an animal is stressed or is sick this gas exchange becomes compromised consequently making cattle more vulnerable.

Let’s review how the respiratory system works.

Air in, air out.
Air in, air out.

Breathing is the function whereby the alveoli cells of the lungs take in oxygen (O2) and eliminate carbon dioxide (CO2). It results in a gaseous interchange (O2 and CO2) between the blood, through the alveolar walls, and the air in the lungs.

Blood circulates through the body via a system of blood vessels. Oxygenated blood eventually reaches all the cells of the body. As a result, the cells are supplied with oxygen, and carbon dioxide from the cells is taken away from the lungs where it is passed into the air and breathed out as waste.

In order to make this process more efficient, the anatomy of the respiratory system is formed by:
Respiratory airways: nasal cavity, nasopharynx, trachea, and bronchial tree; each assist in managing the temperature, humidity and filtration of the inhaled air. This protects against dust particles and irritating gases, before its arrival to the deeper lung tissue: the respiratory bronchioles, pulmonary alveoli and the elastic tissue form the pulmonary system.

The respiratory airways, from the nostrils to the terminal bronchioles, are kept humid by the presence of a layer of mucus produced by the specialized cells (epithelium). The mucus humidifies the air and prevents drying of delicate alveolar cell walls. Mucus also traps particles of dust and other small foreign objects that have found their way into the respiratory tract. Parts of the respiratory system also have cilia cells.

The cilia are hair-like structures on the surface of the cells. These cilia have a wave-like movement that encourages the mucus to flow up the respiratory system.
Eventually, the mucus and the trapped particles are brought up from the lower respiratory system and are either expelled by the coughing process, or removed by internal mechanisms in the respiratory system.
The trachea eventually divides into two bronchi (right and left). The bronchi are tubes that distribute air to the lungs. The bronchi, in turn branch several times forming the bronchioles.

The bronchi are lined with smooth muscle and ciliated epithelium. As already mentioned, the rhythmic beating of the cilia transports mucus and fine particles into the upper respiratory system. The bronchioles diminish in the size with each subdivision as they branch down to respiratory bronchioles which connect to the alveoli. These terminal bronchioles are very narrow, less than one millimeter in diameter.

The alveoli are composed of alveolar ducts, and it is here that they meet with the pulmonary blood vessel system, and gaseous exchange occurs.
Oxygen goes from each alveolus into the blood, and carbon leaves the blood and enters the alveolus.

The respiratory system also functions as a first line of defense using physical barriers such as the cilia and mucus.

The second line of defense occurs in the alveoli and is represented by the cells of the immune system: Macrophages, Neutrophils and Monocytes. Because these cells are associated with inflammation, they are often referred to as inflammatory cells.

In fact, the alveoli have specialized macrophages known as alveolar macrophages (AMs) that patrol and defend the system.

When AMs find foreign material, including pathogenic microorganisms, they may ingest it (phagocytose) and they may release inflammatory chemicals such as cytokines. They may also recruit or attract other inflammatory cells such as neutrophils.
So, once activated, macrophages liberate the cytokines that initiate the further phases of inflammation attracting additional immune cells such as neutrophils, monocytes, and lymphocytes to the site of the initial inflammatory response.

On arrival, these cells release non-specific degrading enzymes and other substances that destroy the pathogen but when overstimulated can harm or even destroy some of the lungs’ own healthy cells.

In the majority of the situations, however, the benefits of the inflammatory process (destruction of invaders) far outweigh any adverse effects on healthy cells. With the end of the infection, and the subsequent reduction in the inflammation, the local tissue returns to a healthy state.

However, in some cases, the inflammatory process can be too intense.
Causing uncontrolled release of great amounts of cytokines that over stimulate the inflammatory process. The result is an extreme inflammation that can help to destroy the invasive pathogenic cells, but can also induce significant damage to the lung tissues resulting in formation of scar and inflammatory tissue.

In situations where the inflammation is intense, therapy with NSAIDS is indicated. NSAIDS have the potential to attenuate destructive inflammation and have minimal side-effects.

2. Pathophysiology of the Bovine Respiratory Disease

The pathogenesis of the Bovine Respiratory Disease (BRD) involves the development of an inflammatory process in the lungs of cattle following infection with certain pathogenic bacteria. The associated pyrexia and subsequent development of pulmonary injuries frequently leads to tissue death or lung consolidation.

The degree and duration of this inflammatory process determine the severity of the disease and specifically whether the illness results in mortality or results in a chronic condition. It also determines whether or not the animal is likely to survive.

Fragile natural defenses or immune suppression, fast bacterial growth and severe inflammation are some common contributors to BRD development.

Anything that harms non-specific physiological mechanisms that normally prevent the bacteria from colonizing in the lungs will increase the risk of BRD developing, as well.

A number of factors can increase stress in cattle including weaning, too much manipulation or movement, long distance transportation, especially without enough food and water, severe ambient conditions, co-mingled cattle, poor ventilation, dietary changes, changes in the herd structure and parasitism.

As stress increases, levels of endogenous corticosteroids increase, and the neutrophils, macrophages T-cells and other lymphocytes are less able to mount an effective immune response.

In addition to bacterial infective agents, viruses commonly implicated in BRD are bovine rhinotracheitis virus (RBV), bovine viral diarrhea virus (BVDV), bovine respiratory syncytial virus (BRSV), and parainfluenza 3 (PI-3). Some recent literature suggests other infective viruses, such as Mycoplasma bovis, rota virus and corona virus agents cause BRD as well.

The bacteria Manheimia haemolytica, Pasteurella multocida and Histophilus somni, can be inhabitants of the respiratory area in healthy animals, and are among the more common bacterial causes of BRD.

Each one contains lipopolysachharides that stimulate the macrophage to release free cytosine and other substances as inflammation is occurring
Cellular chemicals, such as leucotoxin and endotoxin, are also released as immune cells are actively managing the infectious process in BRD infection. The leucotoxin also inhibits phagocytosis and the bacterial death through leucocytes, increasing the colonization rates of uninfected pulmonary tissues by the bacterial pathogens.

An appropriate balance between pro and anti-inflammatory mediators is necessary for endogenous control of pulmonary inflammation
Thus, the immune response of the host animal can, under some circumstances, cause complications more serious than those directly caused by the pathogenic organism.

3. The concept of LPT and the Mechanism of action of Resflor

When clinical signs of BRD are seen, and sub-clinical effects are suspected, Resflor becomes the first choice as the therapeutic tool for Lung Protection Therapy (LPT).

LPT should be considered in appropriate management of BRD – to destroy the causative agent, inducing fast recovery of the animal and protecting the vital pulmonary tissue that will allow normal gas exchange for the remaining life of the animal, and thus reduce economic losses.

Following this concept, Resflor is the first and only true agent that can satisfy all three requirements of LPT.

The bactericidal effects of the florfenicol present in Resflor ensure the rapid elimination of any infectious agents that are colonizing the lungs of cattle. Florfenicol, also appears to be less susceptible than many other antibiotics to the induction of bacterial resistance.

Beyond controlling the infectious agents responsible for BRD, Resflor also modulates the inflammatory response in cattle, thus minimizing lung damage.

Resflor also rapidly reduces pyrexia, bringing the animal quickly to its normal behavior and back to the feed bunk.

Resflor reduces the BRD fever quickly, prevents pulmonary consolidation, and helps the animal to reach to its maximum potential.

4. Resflor: the Product
Resflor is the combination of Florfenicol and Flunixin as an injectable solution for cattle.

Therapeutic indications of this new anti-inflammatory antibiotic combination are: curative treatment of respiratory infections due to Mannheimia haemolytica, Pasteurella multocida and Histophilus somni, associated with fever:

Dosage is 2 ml for 15 kg of weight as a single subcutaneous injection.

The dose volume should not exceed a maximum of 10 ml at any single injection site.

The slaughter withdrawal period is 46 days.

The product is not approved for lactating cattle. But under some circumstances, it can be used in non-lactating dairy cattle.
This is the only combination product with all the benefits of two already proven individual therapeutic products:

- Excellent speed of action for the treatment of BRD and the destruction of the causative bacteria.
- Fast and visible recovery (clinical signals, temperature, food intake)
- Very strong protection for the lungs of the animal: a clinical enhancement for the future growth and economic value of the animal.
- The only way to control adverse impact of BRD with a single product.

Resflor is sold in sizes of 100ml and 250ml and soon it will be available in other sizes. It has a shelf-life of 24 months from the date of manufacture. Resflor acts quickly and is long-acting.

5. The manufacturing of Resflor

We would like to give you a short demonstration of the production steps necessary for the manufacture of a high-quality product: Resflor

Resflor is produced in two of Schering-Plough’s Global Supply Chain units: Frisoythe (Germany) and Segré (France).

In regional and global purchasing, we acquire our raw materials from certified suppliers. Only those raw materials which meet our strict requirements are released for production.

The medicine is manufactured in a stainless steel tank. The different raw materials are added to the tank using varying methods and then blended together. Teams of 2 to 3 people work together assisting and supporting each other. This also ensures that crucial steps are double-checked.
During the manufacturing process, we pay particular attention to clean and hygienic conditions, after all the raw materials have been added to the tank and dissolved, the sterile filtration of Resflor takes place.

During sterile filtration, the solution passes through a pre-filter and then through a sterilizing filter. The pre-filter pre-cleans the product. It is now sterile and is filled into glass vials.

Filling must take place under absolutely germ-free conditions. As we cannot detect microbiological contamination with the naked eye, extensive monitoring for sterility must be carried out during the filling process. For this purpose the air in the sterile area is monitored.

In the filling machine, up to six 500 ml vials can be filled at the same time.
After the vials have been filled, they are closed with a gray stopper and an aluminum cap. This also takes place under absolutely germ-free conditions. The filling process is now complete and the vials leave the sterile area.

The vials are examined by a fully-automated inspection machine. Only those vials which are in perfect condition will be able to pass this test. However, after this, further quality control tests have to be carried out before the batch can be released for sale and packaged.

For example, the filled product is tested for its sterility.
For this purpose a sterility test is carried out using an isolator. The isolator is absolutely germ-free inside.
During this test, the contents of 20 vials are filtered using sterile filters with a pore size of 0.22 micrometers, which is less than one thousandth of a millimeter. This filter is so fine that it will hold back any germs which might be present in Resflor. After the filtration, the filter is carefully placed into a broth solution. By this means the germ becomes visible. After 14 days, it is inspected for sterility.

As a further quality control, we carry out chemical analyses on Resflor. We thereby prove that the correct concentration of active compound is present in our product, and that no undesired derived products were generated during the manufacturing process above acceptable levels. For this purpose, several vials containing Resflor are opened and samples are taken. These samples are then prepared in the laboratory for analysis and are examined by means of an HPLC. With these methods we can detect the slightest deviations from our specifications. The high measurement accuracy of the assay methods allows the detection of minute deviations. This guarantees that the product is formulated to the highest standards of manufacturing.

After Resflor has successfully passed all our quality tests, the vials are labeled. At this stage, the expiration date and the batch number are printed onto the label. By this means, we can trace the history of each vial at a later date.

Resflor is packed into a cardboard shipping container in preparation for the journey to the customer.
Based on the volume of the order and the form of shipment chosen, any means of transport available in modern logistics may be used – ranging from courier service to large sea-freight containers.

The protection of our product has extremely high priority – and this applies to the transport, too. We guarantee the quality of Resflor at all times and in all places.
Whether by sea, on the road, or in the air, Resflor goes on its journey all over the world, where our customers are waiting for it.

Ready to get started?

Join the #1 marketplace for voice-over talent

Need Some Help?

Contact us for help with your voice over project.